Abstract Number: 1154 • 2015 ACR/ARHP Annual Meeting
Ajulemic Acid Is a Novel Cannabinoid That Suppresses the Secretion of TNF-α and IFN-α from the Peripheral Blood Mononuclear Cells of DM Patients In Vitro
Background/Purpose: DM is an autoimmune disease with cutaneous symptoms often accompanied by inflammatory muscle and/or lung disease. Current therapies for DM are often toxic and…Abstract Number: 1885 • 2015 ACR/ARHP Annual Meeting
Identification and Clinical Correlations of Rare Autoantibodies in Systemic Sclerosis and Poly/Dermatomyositis Patients
Background/Purpose: Systemic Sclerosis (SSc), Polymyositis (PM) and Dermatomyositis (DM) are characterized by the presence of serum autoantibodies (autoAbs) which are central in the diagnosis, predicting…Abstract Number: 2363 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Adrenocorticotropic Hormone Gel (Acthar Gel ®) in Refractory Dermatomyositis or Polymyositis
Background/Purpose: Adrenocorticotropic hormone (ACTH) gel (repository corticotropin injection) is a long-acting full sequence ACTH that may include other pro-opiomelanocortin peptides thought to have anti-inflammatory and…Abstract Number: 2369 • 2015 ACR/ARHP Annual Meeting
Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: A Longitudinal Analysis
Background/Purpose: Dermatomyositis (DM) patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are at increased risk of developing interstitial lung disease (ILD). The natural history of…Abstract Number: 2373 • 2015 ACR/ARHP Annual Meeting
Frequency of Antinuclear (ANA), Myositis-Specific (MSA) and Myositis-Associated Antibodies (MAA) in Patients with Idiopathic Inflammatory Myopathies (IIM) from Mexico, Central and South America Centers: Data from the Panlar Myositis Study Group.
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are forms of IIM that involve skeletal muscle as well as many other organs. As in other systemic rheumatic…Abstract Number: 2376 • 2015 ACR/ARHP Annual Meeting
Clinical Features in Dermatomyositis Patients with Novel Autoantibody to Small Ubiquitin-like Modifier Activating Enzymes (Anti-SAE Antibody) and Relationship to Interstitial Lung Disease: A Systematic Review of 29 Cases
Background/Purpose: Anti-SAE antibody is a novel myositis-specific antibody first described in 2007. SAE is an enzyme that facilitates sumoylation, leading to the formation of stable…Abstract Number: 2380 • 2015 ACR/ARHP Annual Meeting
Jo-1 Positive Myositis Patients Tend to Have More Severe Muscle and Lung Involvement Than PM-Scl Positive Patients
Jo-1 positive myositis patients tend to have more severe muscle and lung involvement than PM-Scl positive patients Background/Purpose: Jo-1 and PM-Scl positive myositis patients share…Abstract Number: 2421 • 2015 ACR/ARHP Annual Meeting
Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register
Background/Purpose: Adalimumab (ADA) has become a valuable option for treatment of juvenile idiopathic arthritis (JIA), which significantly improves the outcome of patients. The aim of…Abstract Number: 280 • 2015 ACR/ARHP Annual Meeting
The Fascia Is a Target Organ of Inflammation in Autoimmune Diseases
Background/Purpose: We previously reported that inflammation occurred early in the fascia of patients with dermatomyositis. We often encounter patients with autoimmune diseases who present with…Abstract Number: 282 • 2015 ACR/ARHP Annual Meeting
Angiogenesis in Fasciitis Associated with Dermatomyositis
Background/Purpose: We have previously demonstrated that fasciitis is a common lesion of dermatomyositis (DM) detectable early after disease onset. Furthermore, en bloc biopsy showed that the…Abstract Number: 283 • 2015 ACR/ARHP Annual Meeting
Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases, characterized by muscle fatigue. Despite conventional immunosuppressive treatment including high doses of glucocorticoids, only a…Abstract Number: 2539 • 2014 ACR/ARHP Annual Meeting
Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren’s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis
Background/Purpose: Interferon inducible protein-16 (IFI16) is an intracellular DNA receptor involved in innate immunity. We evaluated the frequency and clinical significance of anti-IFI16 antibodies in…Abstract Number: 2211 • 2014 ACR/ARHP Annual Meeting
Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry
Background/Purpose: The myositis syndromes are rare systemic autoimmune diseases, little is known about their epidemiology. We describe the demographics and comorbidities of patients in a…Abstract Number: 2214 • 2014 ACR/ARHP Annual Meeting
Power Doppler Ultrasonography for Detection of Abnormal Fascial Vascularity: A Potential Early Diagnostic Tool in Fasciitis of Dermatomyositis
Background/Purpose We have previously demonstrated that fasciitis is a common lesion of dermatomyositis (DM) detectable early after disease onset by en bloc biopsy combined with…Abstract Number: 2221 • 2014 ACR/ARHP Annual Meeting
Reduction of Ovarian Reserve in Adult Patients with Dermatomyositis
Background/Purpose: Dermatomyositis (DM) affects female gender during reproductive age, in which ovarian reserve and future fertility are major topics of interest. However, there is no…